EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy
about
Toward the use of precision medicine for the treatment of head and neck squamous cell carcinomaEGFR Activation Leads to Cell Death Independent of PI3K/AKT/mTOR in an AD293 Cell LineReverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer.mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.Oral epithelial stem cells - implications in normal development and cancer metastasis.A new analysis approach of epidermal growth factor receptor pathway activation patterns provides insights into cetuximab resistance mechanisms in head and neck cancerGrape seed extract and resveratrol prevent 4-nitroquinoline 1-oxide induced oral tumorigenesis in mice by modulating AMPK activation and associated biological responsesDeguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.Models for Predicting Stage in Head and Neck Squamous Cell Carcinoma Using Proteomic and Transcriptomic Data.PTPRG suppresses tumor growth and invasion via inhibition of Akt signaling in nasopharyngeal carcinoma.Role of phosphatidylinositol-3-kinase pathway in head and neck squamous cell carcinoma.MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer.The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.An Ultra-Deep Targeted Sequencing Gene Panel Improves the Prognostic Stratification of Patients With Advanced Oral Cavity Squamous Cell Carcinoma.Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure.Dysregulation of splicing proteins in head and neck squamous cell carcinoma.PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma.Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR).MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.The functional significance of microRNA-375 in human squamous cell carcinoma: aberrant expression and effects on cancer pathways.The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib.Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications.mTOR pathway protein immunoexpression as a prognostic factor for survival in head and neck cancer patients: a systematic review and meta-analysis.Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.Could the PI3K canonical pathway be a common link between chronic inflammatory conditions and oral carcinogenesis?Grandinin down-regulates phosphorylation of epidermal growth factor receptor.Down-regulation of Akt by methanol extracts of Impatiens balsamina L. promotes apoptosis in human oral squamous cell carcinoma cell lines.The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.Activation of AKT is associated with metastasis of nasopharyngeal carcinoma.Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.DA6034 promotes gastric epithelial cell migration and wound-healing through the mTOR pathway.Selective inhibition of EGFR downstream signaling reverses the irradiation-enhanced migration of HNSCC cells.GSK1059615 kills head and neck squamous cell carcinoma cells possibly via activating mitochondrial programmed necrosis pathway.
P2860
Q28074691-A54798BC-7DFB-4F05-B29F-AC3453995392Q28551853-8C77F14C-C1CA-4E6F-963B-F90D70DEDFAEQ33637161-708C9463-10FA-4B13-A552-AEBD0753BF51Q34049613-4AF00E1C-5F74-42B7-A193-DAD6F79F537EQ34147649-C3761E8E-ABC0-438C-954F-82C792AB34A7Q34252978-E3C2F61F-5479-4222-8CF7-19CA491F7E90Q34389503-E870880B-A311-4938-8D25-3A79CDC9B55BQ34571304-67087EBC-72B0-42C0-A682-01966CEAB2C7Q35751948-AB6B57F3-B7B3-4BEA-AA9D-BFAD75A1FA94Q35805039-2A674A59-5EA6-499E-B3BF-7BB4D984D709Q35955342-07E39345-9F5B-487F-95D5-D2ED53BD1C8AQ35994228-CE71B67F-1EB1-4DBE-AA23-C9835D6A0212Q36021572-36460A6E-E6CD-46BC-9914-D7BE74FFE5E6Q36029715-8B0E20C1-D6B4-4801-AC0D-BE546F1DE82AQ36215450-17B299E8-17CB-4E30-BC96-54DECC62A487Q36653556-63F6EFE7-A8F8-4306-A3BF-DF00A1281900Q36820341-D6B443DE-2B87-484C-9D55-780188604A68Q36844399-FF602072-71E6-473C-B600-395412FF935BQ37025086-F0C65901-3541-4378-BB2B-FCE2FF1841A4Q37060950-985153AA-2F78-48E6-B521-878F850F7CF2Q37075277-9E953BC6-0FFA-46BE-A984-055519B58157Q37269265-D56055D3-DE58-473F-B744-A9A4DD12CDF4Q37362560-C53C3FA3-CDC0-4BBC-AD09-37B1347CC41AQ37492314-5DD4F1EA-9726-4853-A205-E3C450A1DB70Q37687364-3B6A1B6F-8711-447D-9E0D-8BBD1C71DBCBQ38020381-91622799-7197-44FE-A0D1-F922C3FEF3F0Q38161944-30063731-595D-4500-8CF8-B171DFAE1DB9Q38194548-927C3884-0298-481D-AE0D-0CA46F32FDE6Q38226307-62FEB804-6ACF-40BD-963C-7D7E956D1123Q38667738-A7C82288-BA9A-425F-BCB3-3B2BB1D14343Q38752793-CF800824-4B26-4F7F-872D-992A1B6F148BQ38780033-1242ADFA-F3EC-4D9D-9107-4BE1713692E5Q38945870-FBF7D781-AAC8-4905-90AB-F3C373F23836Q38957423-BC7B1126-0923-4CEC-827C-CEAB8D8BB016Q38995499-10ABE4D1-2804-423D-AB35-4DC099F8524CQ39437368-44DE1541-CA5B-42FB-88F4-04C5E2138C26Q39466612-84E95C4E-BA81-42CE-BBF9-EFDD4B7E4D7EQ39500011-2CAAC5D1-8FAE-44F9-BB32-9BE909A39C56Q40272583-ABD3B0C3-5941-44AB-AE2A-A233ECFE1DF9Q41612466-0714673A-E7B3-4640-BA1F-82BFA2A17E90
P2860
EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy
@ast
EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy
@en
type
label
EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy
@ast
EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy
@en
prefLabel
EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy
@ast
EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy
@en
P2093
P2860
P1476
EGFR-PI3K-AKT-mTOR signaling i ...... for molecular-oriented therapy
@en
P2093
Carter Van Waes
Christian Freudlsperger
Jay A Friedman
Jeffrey R Burnett
Vishnu R Kannabiran
Zhong Chen
P2860
P356
10.1517/14728222.2011.541440
P407
P577
2010-11-26T00:00:00Z